Tag
This review elucidates the contrasting roles of ACADM-mediated fatty acid β-oxidation in atherosclerosis and abdominal aortic aneurysm, highlighting differential lipid metabolism and translational implications for diagnosis and therapy.
An interventional study reveals testosterone’s tissue-specific effects on lipid metabolism, highlighting skeletal muscle as a critical site of metabolic disruption in male hypogonadism and its cardiometabolic implications.
Enhanced lipolysis in synovial fibroblasts marks early pathogenic changes in individuals at risk for rheumatoid arthritis, indicating metabolic shifts precede clinical disease onset.
An epigenome-wide study reveals that DNA methylation markers linked to inflammatory pathways and blood lipid traits play a causal role in abdominal aortic aneurysm development, offering potential for improved risk prediction and therapeutic
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing’s syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.
Pharmacological activation of CXCR7 regulates platelet lipid metabolism, preserves mitochondrial function, and reduces procoagulant activity, offering a novel therapeutic strategy to mitigate thrombotic risk in cardiovascular diseases.
A novel prime editing screening method enables precise functional classification of LDLR gene variants, enhancing diagnosis and therapeutic strategies for familial hypercholesterolemia.
This review synthesizes recent evidence on how colorectal cancer tissues directly absorb extrinsic long-chain fatty acids from the intestinal lumen, particularly in right-sided tumors, and explores the critical interplay between lipid metab
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont
